Search Results - "Chang, Annette M."

Aging and insulin secretion by Chang, Annette M, Halter, Jeffrey B

“…Glucose tolerance progressively declines with age, and there is a high prevalence of type 2 diabetes and postchallenge hyperglycemia in the older population…”
Get more information

Islet autoimmunity identifies a unique pattern of impaired pancreatic beta-cell function, markedly reduced pancreatic beta cell mass and insulin resistance in clinically diagnosed type 2 diabetes by Subauste, Angela, Gianani, Roberto, Chang, Annette M, Plunkett, Cynthia, Pietropaolo, Susan L, Zhang, Ying-Jian, Barinas-Mitchell, Emma, Kuller, Lewis H, Galecki, Andrzej, Halter, Jeffrey B, Pietropaolo, Massimo

“…There is a paucity of literature describing metabolic and histological data in adult-onset autoimmune diabetes. This subgroup of diabetes mellitus affects at…”
Get full text

The GLP-1 Derivative NN2211 Restores β-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose by CHANG, Annette M, JAKOBSEN, Grethe, STURIS, Jeppe, SMITH, Marla J, BLOEM, Cathie J, AN, Bob, GALECKI, Andrzej, HALTER, Jeffrey B

“…The GLP-1 Derivative NN2211 Restores β-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose Annette M. Chang 1 , Grethe Jakobsen 2 ,…”
Get full text

Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D by Blevins, Thomas, Zhang, Qianyi, Frias, Juan P, Jinnouchi, Hideaki, Chang, Annette M

“…To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus lispro in patients with type 2 diabetes on a basal-bolus insulin regimen. This was a…”
Get full text

Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study by Zhang, Qianyi, Chigutsa, Farai, Chang, Annette M.

“…Introduction Ultra-rapid lispro (URLi) is a new prandial insulin lispro formulation. In the PRONTO-T2D study, URLi, in a basal-bolus regimen with glargine or…”
Get full text

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial by Bergenstal, Richard M, Weinstock, Ruth S, Mathieu, Chantal, Onishi, Yukiko, Vijayanagaram, Vishali, Katz, Michelle L, Carr, Molly C, Chang, Annette M

“…Insulin efsitora alfa (efsitora) is a once-weekly basal insulin. This phase 3 study aimed to assess the efficacy and safety of efsitora compared with insulin…”
Get full text

Fasting and postprandial plasma glucose contributions to hemoglobin A1c and time in range in people with diabetes on multiple daily injection insulin therapy: Results from the PRONTO-T1D and PRONTO-T2D clinical trials by Piras de Oliveira, Carolina, Dellva, Mary Anne, Bue-Valleskey, Juliana, Chang, Annette M, Liao, Birong

“…To investigate contributions of changes in fasting plasma glucose (FPG) and postprandial glucose (PPG) to changes in hemoglobin A1c (HbA1c) and time-in-range…”
Get full text

Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5 by Buse, John B, Rodbard, Helena W, Trescoli Serrano, Carlos, Luo, Junxiang, Ivanyi, Tibor, Bue-Valleskey, Juliana, Hartman, Mark L, Carey, Michelle A, Chang, Annette M

“…To evaluate the efficacy and safety of basal insulin peglispro (BIL) versus insulin glargine in patients with type 2 diabetes (hemoglobin A1c [HbA1c] ≤9% [75…”
Get full text

107-LB: Relative Contribution of Fasting Plasma and Postprandial Glucose to HbA1c and TIR in People with T1D on Basal-Bolus Insulin Therapy by PIRAS DE OLIVEIRA, CAROLINA, DELLVA, MARY A., BUE-VALLESKEY, JULIANA M., CHANG, ANNETTE M., CHIGUTSA, FARAI B., LIAO, BIRONG

“…Background: A recent report was published on the contribution of fasting plasma glucose (FPG) and postprandial glucose (PPG) to HbA1c and time in range (%TIR)…”
Get full text

Short-Term Exercise Improves β-Cell Function and Insulin Resistance in Older People with Impaired Glucose Tolerance by Bloem, Cathie J., Chang, Annette M.

“…Background: There is a high prevalence of diabetes and impaired glucose tolerance (IGT) in the older population. Normal aging is associated with insulin…”
Get full text

Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes by Bergenstal, Richard M., Bode, Bruce W., Bhargava, Anuj, Wang, Qianqian, Knights, Alastair W., Chang, Annette M.

“…Introduction To assess time in range (TIR) (70–180 mg/dL) with postprandial glucose (PPG)-focused titration of ultra rapid lispro (URLi; Lyumjev®) in…”
Get full text

Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in Range by Bailey, Timothy S., Bode, Bruce W., Wang, Qianqian, Knights, Alastair W., Chang, Annette M.

“…Introduction To evaluate time in range metrics and HbA1c in people with type 2 diabetes (T2D) treated with ultra rapid lispro (URLi) using continuous glucose…”
Get full text

Relationship of Glucose Variability With Glycated Hemoglobin and Daily Mean Glucose: A Post Hoc Analysis of Data From 5 Phase 3 Studies by Luo, Junxiang, Qu, Yongming, Zhang, Qianyi, Chang, Annette M., Jacober, Scott J.

“…Background: The association of glucose variability (GV) with other glycemic measures is emerging as a topic of interest. The aim of this analysis is to study…”
Get full text

Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials by Rosenstock, Julio, Marre, Michel, Qu, Yongming, Zhang, Shuyu, Bastyr III, Edward J., Prince, Melvin J., Chang, Annette M.

“…Basal insulin peglispro (BIL) is a novel basal insulin with hepato‐preferential action, resulting from reduced peripheral effects. This report summarizes…”
Get full text

Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic Response by Qu, Yongming, Luo, Junxiang, Garhyan, Parag, Antalis, Caryl J., Chang, Annette M., Jacober, Scott J.

“…Background: For new insulin analogs with properties that vary from human insulin, defining activity in units of human insulin based on glycemic lowering…”
Get full text

Performance of an Electronic Diary System for Intensive Insulin Management in Global Diabetes Clinical Trials by Bastyr, 3rd, Edward J, Zhang, Shuyu, Mou, Jiani, Hackett, Andy P, Raymond, Stephen A, Chang, Annette M

“…This report describes the performance of a wireless electronic diary (e-diary) system for data collection and enhanced patient-investigator interactions during…”
Get more information

Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials by Ginsberg, Henry, Cariou, Bertrand, Orchard, Trevor, Chen, Lei, Luo, Junxiang, Bastyr III, Edward J., Bue-Valleskey, Juliana, Chang, Annette M., Ivanyi, Tibor, Jacober, Scott J., Hoogwerf, Byron J.

“…Basal insulin peglispro (BIL) is a novel basal insulin with hepato‐preferential action resulting from reduced peripheral effects. This report provides an…”
Get full text

Time-Averaged Self-Monitored Blood Glucose Values Estimate Hemoglobin A1c Outcomes in Patients With Type 1 Diabetes by Zhang, Shuyu, Fan, Ludi, Zhang, Qianyi, Chang, Annette M., Bastyr, Edward J., Harris, Cynthia J.

Get full text

Impaired β-Cell Function in Human Aging: Response to Nicotinic Acid-Induced Insulin Resistance by Chang, Annette M., Smith, Marla J., Galecki, Andrzej T., Bloem, Cathie J., Halter, Jeffrey B.

“…Context: Glucose tolerance declines with age and may involve impaired β-cell sensitivity to glucose and β-cell compensation for insulin resistance. Objective:…”
Get full text

Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins by Sanyal, Arun, Cusi, Kenneth, Hartman, Mark L, Zhang, Shuyu, Bastyr, Edward J, Bue-Valleskey, Juliana M, Chang, Annette M, Haupt, Axel, Jacober, Scott J, Konrad, Robert J, Zhang, Qianyi, Hoogwerf, Byron J

“…Data on cytokeratin-18 (K-18) and enhanced liver fibrosis (ELF) score in insulin-treated diabetes patients with non-alcoholic fatty liver disease (NAFLD) are…”
Get full text